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CASE REPORT
Cryptic Plasmodium ovale concurrent 
with mixed Plasmodium falciparum 
and Plasmodium malariae infection in two 
children from Central African Republic
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Abstract 
Background: Since several malaria parasite species are usually present in a particular area, co‑infections with more 
than one species of Plasmodium are more likely to occur in humans infected in these areas. In many mixed infections, 
parasite densities of the cryptic species may be low and often not recognized in clinical practice.
Case presentation: Two children (3 and 6 years old) adopted recently from Central African Republic were admitted 
to hospital because of intermittent fever. Thin blood smears stained with Giemsa showed Plasmodium falciparum and 
Plasmodium malariae co‑infection for both children at admission. They were both treated with atovaquone‑proguanil 
combination for 3 days. At day 7, both thin blood smears examination remained negative but at day 28, thin blood 
smear was positive for P. malariae trophozoites and for Plasmodium ovale for the girl and her brother, respectively. 
Samples collected at day 1 and day 28 were submitted to real‑time PCR showing the presence of the three parasite 
species (P. falciparum, P malariae and P. ovale) in admission blood samples from the two children and only P. ovale at 
day 28.
Conclusions: Twenty‑eight days follow‑up after treatment led to detection of a third parasite species in the blood of 
these two patients suggesting covert co‑infection and a delayed appearance of one cryptic species following treat‑
ment. Concurrently infecting malaria species could be mutually suppressive, with P. falciparum tending to dominate 
other species. These observations provide more evidence that recommendations for treatment of imported malaria 
should take into account the risk of concurrent or cryptic infection with Plasmodium species. Clinicians and biologists 
should be aware of the underestimated frequency of mixed infections with cryptic species and of the importance of 
patient follow‑up at day 28. Future guidelines should shed more light on the treatment of mixed infection and on the 
interest of using artemisinin‑based combinations for falciparum and non‑falciparum species.
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Background
Mixed-species malaria infections have received spo-
radic attention [1], and the trend toward malaria control 
in some endemic areas should reduce the occurrence of 
concurrent infection with more than one species of Plas-
modium. However, diagnostic of these mixed-infections 
is rare in clinical practice, and probably underestimated 
by microscopy. Expert microscopists are uncommon in 
clinical laboratory, and distinguishing the species from 
young trophozoite forms of Plasmodium parasites is 
sometimes difficult [2]. The life-threatening P. falcipa-
rum is obviously taking most of the attention consider-
ing the potential consequences of a wrong diagnosis, and 
other species are sometimes scanned with less intensity. 
In case of mixed infection, the concurrent species is 
mostly below the threshold of microscopy. For example, 
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the ratio of Plasmodium malariae/P. falciparum was 
described as extremely low in a study conducted in Ivory 
Coast and the protective effect of lengthy subclinical P. 
malariae infections was suspected [3]. Moreover, the 
liver stage of Plasmodium vivax and Plasmodium ovale, 
which are responsible for relapses, are not detectable [1]. 
The delayed appearance of a cryptic species after suc-
cessful treatment of the first diagnosed species has been 
reported in area endemic for P. falciparum and P. vivax 
malaria [4].
It has been known from decades that antagonism 
between species may lead to a rapid decrease of circulat-
ing parasites, such as P. malariae when inoculated with P. 
vivax in an attempt to treat neurosyphilis [5].
Triple species infection are known, but remain rare in 
the literature. Two parallel cases of triple infections (P. 
falciparum and P. malariae, followed by P. ovale delayed 
infection) in two adopted children from Central African 
Republic are presented here to document the risk of late 
reappearance and the need for clinical and parasitologi-
cal follow-up. These cases focused more light on the risk 
of treating each malaria species by drugs with different 
efficacy.
Case report
Two children (3 and 6 years old) were admitted to hospi-
tal because of intermittent fever and suspected malaria. 
They have been adopted recently and came back from 
Central African Republic a week previously.
The 6-year-old boy presented with a temperature of 
37.9 °C, a systolic murmur in mitral focus, and a hepato-
splenomegaly. The haemoglobin level was 6.7  g/dL, the 
mean corpuscular volume was 65 fL, and the platelet 
count was 216 G/L. Biochemical tests showed a normal 
liver function, increased serum levels of lactate dehy-
drogenase (291 U/L, reference range 135–250 U/L) and 
C-reactive protein (73, reference value <5). A coagulation 
test result for the prothrombin time–international nor-
malized ratio was slightly prolonged (14.7 s with a ratio at 
67%, reference range 12.5 s with a ratio at 75–100%). An 
ultrasonographic abdominal examination showed hepa-
tomegaly (107  mm thickness along the mammary line, 
reference value for this age 90  mm), and splenomegaly 
(115 mm, reference range 70–96 mm), and lack of deep 
lymph nodes. An ultrasonographic heart examination 
reported no abnormalities.
The 3-year-old girl, presented with a temperature of 
37 °C, bilateral crackles predominant right, and a hepato-
splenomegaly. The haemoglobin level was 6.3  g/dL, the 
mean corpuscular volume was 71.6 fL, and the platelet 
count was 138 g/L. Biochemical tests showed a normal 
liver function, increased serum levels of lactate dehydro-
genase (379 U/L) and C-reactive protein (48 mg/mL). A 
coagulation test result for the prothrombin time–inter-
national normalized ratio was slightly normal. Ultrasono-
graphic abdominal examination reported a splenomegaly 
(100 mm, and lack of deep lymph nodes.
Thin blood smears stained with Giemsa showed P. falci-
parum and P. malariae co-infection for both children (P. 
falciparum 1.3% +  P. malariae 0.14% and P. falciparum 
0.03% + P. malariae 0.15% for girl and boy, respectively). 
A rapid diagnostic test (Palutop4 +, AllDiag, Strasbourg, 
France) showed three positive bands for the control, 
Plasmodium spp. (pLDH), and P. falciparum (pHRPII) 
markers.
Both children received 1 adult co-formulated tablet of 
Malarone, containing 250  mg atovaquone and 100  mg 
proguanil hydrochloride, per day for 3 days. The tablets 
were administered during the meal without addition 
of fat. The boy weighed 19  kg, the girl weighed 14.5  kg 
and the administered weight-based dose of atovaquone/
proguanil was 10/5 and 17/7 mg/kg/day for the boy and 
girl respectively. They did not vomit and no other adverse 
events were noted during treatment. Both children 
received iron syrup supplementation and paracetamol.
Almost complete parasitaemia clearance was obtained 
at day 3 (P. falciparum <0.01% + P. malariae <0.01% and 
P. falciparum 0% +  P. malariae 0.02%, for girl and boy 
respectively). These figures are not uncommon because 
atovaquone-proguanil is known to act relatively slowly. 
Apyrexia was obtained at day 2 and patients were dis-
charged on day 5 and did not return until scheduled 
appointments for control of parasitaemia on day 7.
At day 7, both thin blood smears examination remained 
negative, while few picnotic parasites were detected on 
thick blood smears. Surprisingly, at day 28, thin blood 
smear from the girl was positive and revealed  <0.01% 
P. malariae trophozoites while P. ovale (<0.01%) was 
detected from her brother’s blood. To confirm the species 
identification, the samples collected at day 1 and day 28 
were submitted to real-time PCR as previously described 
[6]. Molecular diagnosis demonstrated the presence of 
the three parasite species (P. falciparum, P. malariae and 
P. ovale) in D0 samples from both children, and only P. 
ovale at day 28.
Both children were still apyretic and didn’t show any 
symptoms of infection. Considering the suspected para-
sitological failure of the atovaquone-proguanil treat-
ment against P. ovale, patients were given a total dose of 
25 mg/kg of chloroquine over 3 days. Both children were 
not glucose-6-phosphate dehydrogenase-deficient, but 
primaquine was not used to prevent relapses. Clinical 
and parasitological follow-up was performed and total 
parasite clearance was assessed by thin and thick blood 
smears at day 42, showing the absence of recurrence. 
Both children had non-haemolytic (normal haptoglobin), 
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microcytic anaemia at admission to hospital and were 
found to have iron deficiency, which was successfully 
treated after 3 months of iron supplementation. Echocar-
diography examinations revealed that boy had an inor-
ganic heart murmur. Gastrointestinal helminths were not 
found after 3 stool examinations for ova and parasites. 
Cysts of Entamoeba coli and Chilomastix mesnili were 
found in the boy’s stools, who was treated with secnida-
zole. Patients were then lost to follow-up.
Conclusion
Six different malaria species are known to infect humans: 
P. falciparum, P. vivax, P. malariae, P. ovale wallikeri, P. 
ovale curtisi and P. knowlesi [7]. Routine microscopical 
examination of thick and/or thin blood smears stained 
with Giemsa allows discrimination of four of these spe-
cies, since P. ovale wallikeri is not distinguishable from 
P. ovale curtisi, and P. knowlesi is impossible to distin-
guish from P. malariae. Most of the rapid diagnostic tests 
available on the market showed lower performance for 
P. vivax (70.7% panel detection score) than for P. falcipa-
rum (85% panel detection score) in the round 6 of WHO 
[8]. Plasmodium ovale and P. malariae RDTs have not 
been evaluated so far. Molecular tests are the only meth-
ods allowing species identification with a good accuracy.
Mixed, or concurrent infections, are frequently reported 
in epidemiological studies conducted in endemic areas and 
probably underdiagnosed at an individual level. It is known 
that several Anopheles species, are able to carry more than 
one species, including the four main species for Anopheles 
gambiae [9]. There is no definitive evidence of a clinical or 
parasitological impact of mixed infections in humans. Plas-
modium vivax is supposed to reduce the severity of P. fal-
ciparum infection; P. falciparum reduces the availability of 
red blood cells for P. vivax infection, and a theory of species-
transcendenting density-dependant (STDD) regulation of 
multiple malaria infection has been proposed [10, 11].
There is no evidence that drugs used to treat the domi-
nant specie may be ineffective against the cryptic species. 
Since ACTs are mainly recommended to treat falcipa-
rum malaria, and chloroquine to treat non-falciparum 
malaria, under-diagnosis of mixed infection may lead to 
inappropriate treatment of patients. In countries with 
chloroquine-resistant P. vivax, ACT is the treatment 
policy for non-falciparum infections. ACT is also rec-
ommended treatment of mixed infections [12]. In the 
two cases presented here, P. falciparum and P. malariae 
co-infection was successfully treated with atovaquone-
proguanil, while asymptomatic P. ovale was detected 
at day 28. Unfortunately, it was not possible to know if 
the recurrence of P. ovale was due to drug resistance or 
relapse of liver stages, and cytochrome b gene mutation 
was not investigated due to low amount of samples. A 
plausible cause of this late therapeutic failure is the rela-
tively insufficient dosage due to increased oral clearance 
of atovaquone in pediatric patients. However, failure to 
atovaquone-proguanil prophylaxis has been reported in 
travelers presenting P. ovale infection [13].
These observations provide more evidence that recom-
mendations for treatment of imported malaria may take 
into account the risk of concurrent or cryptic infection 
with Plasmodium species presenting different sensitivity 
to drugs. Considering that information on drug resist-
ance of non-falciparum species is scarce, clinician and 
biologists should take particular attention to patient fol-
low-up at day 28.
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